研究者詳細 - 金沢　賢也

論文 - 金沢　賢也

分割表示540 件中 141 - 160 件目／全件表示 >>

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.

Sato Y, Tanino Y, Nikaido T, Togawa R, Kawamata T, Watanabe N, Sato R, Yamada R, Onuma T, Tomita H, Saito M, Rikimaru M, Morimoto J, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamada S, Hashimoto Y, Shibata Y

BMC pulmonary medicine 22 ( 1 ) 191 2022年5月

Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.

Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Ishii T, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Kanbe T, Kanzaki N, Azuma T, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Tsukada Y, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Umeda T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Iseki K

International journal of medical sciences 19 ( 5 ) 834 - 841 2022年（ ISSN:14491907 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.

Kotake M, Imai H, Kaira K, Endoh H, Yamada Y, Kaburagi T, Kiyoshima M, Sugiyama T, Nakamura Y, Kasai T, Matsuguma H, Minemura H, Kanazawa K, Suzuki H, Fujita A, Minato K

Chemotherapy 67 ( 3 ) 142 - 151 2022年（ ISSN:0009-3157 ）

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H

Frontiers in oncology 12 1080729 2022年（ ISSN:2234-943X ）

　前のページ - 次のページ　

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27